Shopping Cart 0
Cart Subtotal
AED 0

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 25690

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 38535
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Pipeline Review, H2 2018

Summary

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 4-Pipeline Review, H2 2018, outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. It acts via the formation of large multiprotein complexes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Cardiovascular which include indications Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colon Cancer, Congestive Heart Failure (Heart Failure), Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Gallbladder Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Liver Cancer, Lung Cancer, Mycosis Fungoides, Myelodysplastic Syndrome, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer and Sezary Syndrome.

Furthermore, this report also reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)

- The report reviews Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

- The report assesses Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Overview

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Companies Involved in Therapeutics Development

4SC AG

AlfaSigma SpA

HitGen LTD

MEI Pharma Inc

Mirati Therapeutics Inc

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Drug Profiles

Gene Therapy to Activate HDAC4 for Heart Failure-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HG-3001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mocetinostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pracinostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resminostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-3595-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Dormant Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Discontinued Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Product Development Milestones

Featured News & Press Releases

Nov 05, 2018: Mirati to present new data from ongoing phase 2 clinical trial on mocetinostat and durvalumab at the SITC 33rd Annual Meeting

Nov 01, 2018: MEI Pharma to present data from Phase 2 trial of Pracinostat at ASH 2018

May 31, 2018: MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients

May 30, 2018: Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit f

Jan 31, 2018: Positive DSMB safety review of 4SC's pivotal RESMAIN study of resminostat in CTCL

Jan 11, 2018: Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)

Dec 20, 2017: 4SC receives Pediatric Investigation Plan Waiver for resminostat in CTCL from the European Medicines Agency

Dec 13, 2017: 4SC receives milestone payment from Immunic

Oct 12, 2017: Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients

Oct 10, 2017: Resminostat demonstrates potential to significantly alleviate itching in CTCL patients

Sep 13, 2017: Phase I study of 4SC's resminostat indicates efficacy in biliary tract cancer

Aug 02, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Jun 14, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome

Jun 05, 2017: Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by 4SC AG, H2 2018

Pipeline by AlfaSigma SpA, H2 2018

Pipeline by HitGen LTD, H2 2018

Pipeline by MEI Pharma Inc, H2 2018

Pipeline by Mirati Therapeutics Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Therapeutic Products under Development, Key Players in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Therapeutics, Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Pipeline Overview, Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Pipeline, Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Pipeline Assessment


Companies

4SC AG

AlfaSigma SpA

HitGen LTD

MEI Pharma Inc

Mirati Therapeutics Inc

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Pipeline Review, H2 2018

Summary

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 4-Pipeline Review, H2 2018, outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. It acts via the formation of large multiprotein complexes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Cardiovascular which include indications Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colon Cancer, Congestive Heart Failure (Heart Failure), Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Gallbladder Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Liver Cancer, Lung Cancer, Mycosis Fungoides, Myelodysplastic Syndrome, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer and Sezary Syndrome.

Furthermore, this report also reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)

- The report reviews Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

- The report assesses Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Overview

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Companies Involved in Therapeutics Development

4SC AG

AlfaSigma SpA

HitGen LTD

MEI Pharma Inc

Mirati Therapeutics Inc

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Drug Profiles

Gene Therapy to Activate HDAC4 for Heart Failure-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HG-3001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mocetinostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pracinostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resminostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-3595-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Dormant Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Discontinued Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Product Development Milestones

Featured News & Press Releases

Nov 05, 2018: Mirati to present new data from ongoing phase 2 clinical trial on mocetinostat and durvalumab at the SITC 33rd Annual Meeting

Nov 01, 2018: MEI Pharma to present data from Phase 2 trial of Pracinostat at ASH 2018

May 31, 2018: MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients

May 30, 2018: Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit f

Jan 31, 2018: Positive DSMB safety review of 4SC's pivotal RESMAIN study of resminostat in CTCL

Jan 11, 2018: Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)

Dec 20, 2017: 4SC receives Pediatric Investigation Plan Waiver for resminostat in CTCL from the European Medicines Agency

Dec 13, 2017: 4SC receives milestone payment from Immunic

Oct 12, 2017: Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients

Oct 10, 2017: Resminostat demonstrates potential to significantly alleviate itching in CTCL patients

Sep 13, 2017: Phase I study of 4SC's resminostat indicates efficacy in biliary tract cancer

Aug 02, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Jun 14, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome

Jun 05, 2017: Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by 4SC AG, H2 2018

Pipeline by AlfaSigma SpA, H2 2018

Pipeline by HitGen LTD, H2 2018

Pipeline by MEI Pharma Inc, H2 2018

Pipeline by Mirati Therapeutics Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Therapeutic Products under Development, Key Players in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Therapeutics, Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Pipeline Overview, Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Pipeline, Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Pipeline Assessment


Companies

4SC AG

AlfaSigma SpA

HitGen LTD

MEI Pharma Inc

Mirati Therapeutics Inc